Racionalna primjena serumskih tumorskih biljega u dijagnostici i liječenju solidnih tumora

Scientific paper - Review paper

• Title (english): Rational use of serum tumour markers in diagnostics and treatment of solidtumours
• Author: Natalija Dedić Plavetić
• Author: Milena Gnjidić
• Author: Ana Kulić
• Author: Marija Ivić
• Author: Ivana Kukec
• Author: Marina Vidović
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners, surgeons, oncologists, and other health care professionals giving care to patients with solid tumours.

Abstract (croatian)

Optimalno zbrinjavanje oboljelih od malignih bolesti, ovisno o vrsti tumora, uključuje i određivanje serumskih tumorskih biljega. Ti su biljezi heterogena skupina molekula čija je koncentracija povišena kod ljudi oboljelih od zloćudnih tumora, ali se u niskim koncentracijama mogu naći i u plazmi zdravih pojedinaca. Povišene koncentracije u plazmi nastaju zbog: promjena u samoj stanici, nekroze stanice te promjene izražaja ili izlučivanja različitih molekula. Kod nekih tumora same tumorske stanice mogu potaknuti druge stanice na lučenje određenih spojeva. U kliničkoj primjeni u ovom je trenutku između ostalih dostupno određivanje nekoliko serumskih tumorskih biljega: CEA, CA 19-9, CA 15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH i tiroglobulin. Veći broj serumskih tumorskih biljega primjenjuje se eksperimentalno i čeka svoje mjesto u svakodnevnoj kliničkoj primjeni. Smjernice o primjeni tumorskih biljega Nacionalne akademije kliničke biokemije (National Academy of Clinical Biochemistry – NACB) osmišljene su da bi poticale prikladniju upotrebu testova tumorskih biljega od liječnika primarne zaštite, kirurga, onkologa, ginekologa te ostalih specijalista koji se bave bolesni­cima sa solidnim tumorima.

• Keywords (english): Biomarkers, Tumor/blood; Biomarkers, Tumor/classification; Humans; Neoplasms/blood; Neoplasms/classification; Neoplasms/diagnosis; Neoplasms/therapy; Patient Care Management/methods; Patient Care Management/standards; Practice Guidelines as Topic
• Language: croatian
• Publication type: Scientific paper - Review paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Liječnički vjesnik
• Numbering: vol. 138, no. 3-4, pp. 85-92
• p-ISSN: 0024-3477
• URN:NBN: urn:nbn:hr:105:147689
• Publication: 2016-03
• Document URL: https://hrcak.srce.hr/file/255054
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-28 09:35:53